Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's performance is steadily growing, with the upward trend in uranium prices and the synchronization of long-term contract renewals releasing profit elasticity [5] - The company is expected to benefit from the global recovery in nuclear power, leading to sustained growth in natural uranium demand [7] - The company is backed by CGN Group, providing both market and resource advantages, with future uranium prices expected to remain high [7] Financial Summary - For 2026, the projected revenue is 11,849.71 million HKD, with a year-on-year growth rate of 72.5% [6] - The projected net profit attributable to shareholders for 2026 is 986.85 million HKD, reflecting a year-on-year increase of 118.0% [6] - The earnings per share for 2026 is estimated at 0.13 HKD, with a return on equity (ROE) of 17.8% [6] - The company’s total market capitalization is approximately 29,338.64 million HKD, with a debt-to-asset ratio of 47.64% [3][6] Operational Insights - In 2025, the company achieved a total uranium sales volume of approximately 4,611 tons, with a significant recovery in trading profits due to rising uranium prices in the second half of the year [7] - The average sales price for self-produced uranium was approximately 71.8 USD/pound, while the average sales price for international trade was about 74.7 USD/pound [7] - The company has locked in approximately 245 million HKD in trade profits from pending sales contracts by the end of 2025, providing a degree of performance assurance for the future [7]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company achieved rapid growth in 2025, with revenue reaching 20.875 billion yuan, a year-on-year increase of 31.8%, and net profit attributable to shareholders of 4.415 billion yuan, up 32.72% year-on-year [5] - The "1+6" multi-category strategy has shown initial success, with significant results in national and global expansion [5] - The company has successfully covered 100% of prefecture-level cities in China and has over 3,400 distributors and 4.5 million terminal points [6] Financial Performance - In 2025, the beverage business generated revenue of 20.859 billion yuan, with energy drinks, electrolyte drinks, and other beverages contributing 15.599 billion, 3.274 billion, and 1.986 billion yuan respectively, showing year-on-year growth of 17.25%, 118.99%, and 94.08% [6] - The gross profit margin improved to 44.91%, with a net profit margin of 21.14% [6] - The company expects net profit attributable to shareholders to reach 5.450 billion, 6.627 billion, and 7.709 billion yuan in 2026, 2027, and 2028 respectively, with corresponding growth rates of 23.42%, 21.61%, and 16.33% [7] Market Position - The company has increased its market share in China's energy drink sector, with sales volume share rising from 47.9% in 2024 to 51.6% in 2025 [6] - The electrolyte drink "Bu Shui La" has entered the 3 billion yuan sales category, while "Guo Zhi Cha" and "Dongpeng Daka" have both surpassed 500 million yuan in revenue [6] Strategic Developments - The company successfully listed on the Hong Kong Stock Exchange on February 3, 2026, marking the beginning of its dual listing strategy [6] - A strategic cooperation agreement was signed with Indonesian conglomerate Sanlin Group to enhance overseas supply chain and sales network [6]

Robotics - The core advancement in Xiaomi's robotic dexterous hand includes a tactile coverage area of 8200 square millimeters, enhancing full palm perception and efficient data collection [2][8] - The demand for high-performance actuators is expected to surge due to the public unveiling of the "machine wolf" combat training footage, indicating a shift towards more complex operational scenarios [9] - The humanoid robotics industry is anticipated to transition from small-scale validation to a new phase of growth, with significant attention on upstream components and main manufacturers [9][10] Consumer Electronics - Xtep International reported a revenue of 14.15 billion yuan for 2025, reflecting a year-on-year increase of 4.2%, with a net profit of 1.37 billion yuan, up 10.8% [13][14] - The company maintains a strong dividend policy with a payout ratio exceeding 50%, indicating robust shareholder returns [14][15] - The professional sports segment, including brands like Saucony and Maile, saw a revenue increase of 30.8%, highlighting a successful high-end positioning strategy [15][16] Food and Beverage - Weilian Meiwai achieved a revenue of 7.224 billion yuan in 2025, marking a 15.3% year-on-year growth, with a net profit increase of 33.4% [18][19] - The company’s vegetable products segment, particularly the konjac category, has driven significant growth, with a notable increase in offline distribution efficiency [19][20] - The company is exploring overseas markets, with international revenue growing by 48% in 2025, indicating potential for further expansion [19][20] New Consumption - Ruoyuchen reported a total revenue of 3.432 billion yuan in 2025, a remarkable growth of 94.35%, with self-owned brands contributing significantly to this increase [21][22] - The self-owned brand segment achieved a revenue of 1.813 billion yuan, up 261.94%, underscoring its role as a key growth driver [22][23] - The brand management and e-commerce operations have shown strong development, with revenue contributions of 895 million yuan and 723 million yuan, respectively [23][24] Utilities and Environmental Protection - China Coal Energy reported a revenue of 148.06 billion yuan for 2025, a decrease of 21.8%, with a net profit of 17.88 billion yuan, down 7.3% [26][27] - The company has focused on cost reduction strategies to mitigate the impact of declining coal prices, achieving a unit sales cost of 252 yuan per ton, down 10.7% year-on-year [27][28] - The company anticipates a rebound in coal prices and chemical product prices in 2026, which could enhance profitability [28][30] Transportation - COSCO Shipping Special reported a revenue of 23.211 billion yuan for 2025, reflecting a growth of 38.32%, with a net profit of 1.78 billion yuan, up 16.29% [33][34] - The multi-purpose vessel segment remains a stable revenue source, contributing approximately 57.17% of total revenue, with new vessel acquisitions expected to drive further growth [34][35] - The company plans to expand its fleet significantly, with expectations to increase its total cargo volume to over 31 million tons by 2026 [35][36] Pharmaceuticals - WuXi XDC, a leading CRDMO in the bioconjugate drug sector, reported a revenue of 5.944 billion yuan for 2025, a 46.7% increase, with a net profit margin improvement [38] - The company has seen a significant rise in its order backlog, with a total of 252 projects, indicating strong future growth potential [38]

Group 1 - Investment Rating: The report suggests to pay attention to Chuangda New Materials, focusing on high-performance thermosetting composite materials [42] - Core Viewpoint: Chuangda New Materials is a leading enterprise in power and optoelectronic semiconductor packaging materials, driven by growth in downstream automotive electronics and other sectors [2][42] - Issuance Information: The issuance price is 19.58 CNY per share with a price-to-earnings ratio of 14.72X, and the total number of shares issued is 12.33 million, accounting for 25% of the total share capital post-issuance [6][7] Group 2 - Company Overview: Chuangda New Materials focuses on the electronic packaging field, with a steady growth in revenue and profit, and has developed a competitive position in the domestic market [11] - Product Application: The main products include epoxy molding compounds, liquid epoxy encapsulants, and other electronic packaging materials, widely used in semiconductor, automotive electronics, and other electronic applications [12][14] - Financial Performance: The company’s net profit is expected to reach 65.6 million CNY in 2025, with a compound annual growth rate (CAGR) of 42% from 2022 to 2025 [24][26] Group 3 - Industry Overview: The global semiconductor packaging materials market is projected to reach 24.6 billion USD in 2024, benefiting from the recovery of the semiconductor market and increasing demand for advanced materials [29][30] - Downstream Demand: The demand for packaging materials is expected to grow due to the expansion of power semiconductors and optoelectronic semiconductors, as well as automotive electronics [29][36] - Competitors: Key competitors in the industry include Huahai Chengke, Kaihua Materials, and Kangmite, with differences in specific product offerings and revenue structures [39][40]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The main business of gypsum board is under pressure, while the "two wings" businesses are becoming growth engines [5] - The company faced revenue decline due to downstream demand pressure and changes in industry competition, leading to a decrease in gross and net profit margins starting from the second quarter [7] - The company’s performance in 2025 showed a total revenue of 252.80 billion yuan, down 2.09% year-on-year, and a net profit of 29.06 billion yuan, down 20.31% year-on-year [7] Financial Summary - For 2026, the estimated revenue is 25,809 million yuan, with a year-on-year growth rate of 2.09% [6] - The estimated net profit for 2026 is 2,811 million yuan, with a year-on-year decline of 3.28% [6] - The estimated earnings per share (EPS) for 2026 is 1.65 yuan [6] - The company’s return on equity (ROE) is projected to be 9.75% in 2026 [6] - The price-to-earnings (P/E) ratio is estimated to be 15.76 for 2026 [6] Segment Performance - Gypsum board segment revenue was 119.63 billion yuan in 2025, down 8.73% year-on-year, with a gross margin of 36.90% [7] - The revenue from the metal framework segment was 19.72 billion yuan, down 13.74% year-on-year [7] - The waterproof membrane segment achieved revenue of 33.14 billion yuan, down 0.24% year-on-year [7] - The paint segment saw revenue growth of 22.99% year-on-year, reaching 50.93 billion yuan, attributed to the integration of Zhejiang Bridge Paint and the high-end positioning of Jiaboli [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The company achieved a net profit growth of 37% year-on-year in 2025, driven by both skincare and makeup segments [5][8] - The total revenue for 2025 was 5.05 billion RMB, representing a year-on-year increase of 30.01% [8] - The company maintains a gross margin of 84.22%, which is relatively stable compared to the previous year [8] Financial Performance - Revenue projections for the upcoming years are as follows: - 2026: 6.49 billion RMB (growth of 28.5%) - 2027: 8.19 billion RMB (growth of 26.3%) - 2028: 9.83 billion RMB (growth of 20.0%) [7] - Net profit forecasts are: - 2026: 1.56 billion RMB (growth of 29.9%) - 2027: 2.01 billion RMB (growth of 28.5%) - 2028: 2.47 billion RMB (growth of 22.9%) [7] - Earnings per share (EPS) is projected to be 3.19 RMB in 2026, 4.10 RMB in 2027, and 5.04 RMB in 2028 [7] Business Segments - Skincare revenue in 2025 was 1.87 billion RMB, up 31.1% year-on-year, with key products contributing significantly [8] - Makeup revenue reached 3.00 billion RMB, also reflecting a 30.0% increase year-on-year, with several products achieving over 1 billion RMB in retail sales [8] - The company is expanding its high-end department store channels and has a total of 445 self-operated counters [8] Market Position - The company has been recognized as the top domestic makeup brand during major shopping festivals on platforms like Douyin [8] - The brand is enhancing its high-end positioning with new fragrance products, contributing additional revenue [8] Profitability and Cost Management - The company’s net profit margin improved to 23.9%, an increase of 1.2 percentage points year-on-year [8] - The sales expense ratio decreased to 48.3%, indicating effective cost management and scale effects [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady revenue growth in the mass market, with a 4.2% increase in revenue for 2025, reaching 14.15 billion RMB, and a net profit of 1.37 billion RMB, up 10.8% year-on-year [7] - The professional sports segment, including brands like Saucony and Merrell, has experienced significant growth, with a 30.8% increase in revenue to 1.64 billion RMB [7] - E-commerce continues to drive growth, with strong performance in overseas markets, where revenue nearly doubled, and cross-border e-commerce revenue increased by over 220% [7] - The company maintains a strong dividend policy, with a payout ratio above 50%, indicating a commitment to returning value to shareholders [7] Financial Summary - Revenue projections for the company are as follows: 14,932.66 million RMB in 2026, 15,819.11 million RMB in 2027, and 16,865.95 million RMB in 2028, with growth rates of 5.52%, 5.94%, and 6.62% respectively [6][8] - The forecasted net profit for 2026 is 1.30 billion RMB, with a slight decline of 5.3%, followed by a recovery with growth rates of 13.2% and 12.4% in 2027 and 2028 [6][8] - The company's return on equity (ROE) is projected to be 11.99% in 2026, improving to 13.37% by 2028 [6][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company achieved stable performance in 2025, with total revenue of 7.224 billion yuan, a year-on-year increase of 15.3%, and a net profit attributable to shareholders of 1.425 billion yuan, up 33.4% [5] - The growth in revenue was driven by the konjac product category, which led to a significant increase in the vegetable product segment, accounting for 62.4% of total revenue, up 8.6 percentage points year-on-year [6] - The company is focusing on product innovation and exploring overseas markets, with overseas revenue reaching 117 million yuan, a year-on-year increase of 48% [7] Financial Performance - In 2025, the company reported a gross margin of 48.0%, with a slight decrease of 0.1 percentage points year-on-year, while the net profit margin increased by 2.7 percentage points to 19.7% [7] - The company plans to distribute dividends totaling approximately 851 million yuan, corresponding to a payout ratio of 60% [5] - The forecast for net profit attributable to shareholders for 2026-2028 is 1.64 billion, 1.90 billion, and 2.14 billion yuan, with respective growth rates of 15.1%, 15.7%, and 12.9% [8]

Investment Rating - The report assigns a "Buy" rating for WuXi XDC (02268.HK) as it is the first coverage of the company [5] Core Views - The XDC industry remains vibrant, with continuous high investment in capacity and leading technology [5] - WuXi XDC is a global leader in bioconjugate drug contract research, development, and manufacturing (CRDMO), with strong revenue growth and profitability [7] - The company has a robust project pipeline and has signed numerous comprehensive projects, indicating strong future growth potential [7] Financial Performance Summary - Revenue projections for WuXi XDC are as follows: - 2024: 4,052 million RMB (90.80% YoY growth) - 2025: 5,944 million RMB (46.69% YoY growth) - 2026E: 8,032 million RMB (35.12% YoY growth) - 2027E: 10,811 million RMB (34.60% YoY growth) - 2028E: 14,139 million RMB (30.78% YoY growth) [6] - Net profit projections are as follows: - 2024: 1,070 million RMB (277.24% YoY growth) - 2025: 1,480 million RMB (38.41% YoY growth) - 2026E: 2,010 million RMB (35.76% YoY growth) - 2027E: 2,859 million RMB (42.26% YoY growth) - 2028E: 3,815 million RMB (33.43% YoY growth) [6] - Earnings per share (EPS) projections are: - 2024: 0.89 RMB - 2025: 1.22 RMB - 2026E: 1.60 RMB - 2027E: 2.27 RMB - 2028E: 3.03 RMB [6] Growth Drivers - The company has a strong order backlog, with an unfulfilled order amount of 1.489 billion USD as of December 31, 2025, reflecting a 50.3% YoY increase [7] - The number of drug discovery phase projects has significantly increased, from 681 projects in 2024 to 1,039 projects in 2025 [7] - WuXi XDC is expanding its global footprint with new production capacities and strategic acquisitions, including the acquisition of Dongyao Pharmaceutical [7]

Investment Rating - The industry investment rating is "Positive" (maintained) [4] Core Insights - The humanoid robot industry is expected to transition from small-scale validation to a new phase of "1-10" production, indicating a significant shift towards mass production and commercialization [6][42] - Key components in the supply chain are likely to benefit from cost advantages, with high-value and strong certainty in demand for parts such as joint modules, screws, and reducers [4][42] - The demand for tactile sensors is anticipated to rise as advancements in flexible sensing technology continue, particularly with developments from companies like Xiaomi and Fulei New Materials [6][14] Summary by Sections Section 1: Humanoid Robot Developments - Xiaomi's robotic hand has expanded its tactile sensor coverage to 8200 square millimeters, enhancing its operational capabilities [9][10] - Fulei New Materials has secured a significant order for 100,000 tactile sensors, indicating strong market recognition and potential for growth in the flexible sensing sector [14][15] Section 2: Market Dynamics - The latest generation of quadruped robots, known as "Machine Wolves," is evolving to meet more complex operational demands, which is expected to drive the need for high-performance actuators [19][25] - The industry is witnessing a shift towards collective and grouped applications of quadruped robots, enhancing their operational capabilities in various environments [23][25] Section 3: Financial Performance - The humanoid robot core industry chain index has shown a significant increase of 172.27% since September 24, 2024, despite a recent decline of 0.54% [28][30] - Notable stock performances include Tianzhong Precision (+23.84%) and Weike Technology (+18.58%), while companies like Fuhua Co. and Woan Robotics have seen declines [31][33] Section 4: Future Events - Key upcoming events include the anticipated launch of Tesla's Optimus V3 in 2026 and the World Artificial Intelligence Conference in Shanghai [41]